dc.creator | Giamouzis G., Dimos A., Xanthopoulos A., Skoularigis J., Triposkiadis F. | en |
dc.date.accessioned | 2023-01-31T07:41:37Z | |
dc.date.available | 2023-01-31T07:41:37Z | |
dc.date.issued | 2022 | |
dc.identifier | 10.1007/s10741-021-10134-5 | |
dc.identifier.issn | 13824147 | |
dc.identifier.uri | http://hdl.handle.net/11615/72280 | |
dc.description.abstract | Sudden cardiac death (SCD) is among the leading causes of death worldwide, and it remains a public health problem, as it involves young subjects. Current guideline-directed risk stratification for primary prevention is largely based on left ventricular (LV) ejection fraction (LVEF), and preventive strategies such as implantation of a cardiac defibrillator (ICD) are justified only for documented low LVEF (i.e., ≤ 35%). Unfortunately, only a small percentage of primary prevention ICDs, implanted on the basis of a low LVEF, will deliver life-saving therapies on an annual basis. On the other hand, the vast majority of patients that experience SCD have LVEF > 35%, which is clamoring for better understanding of the underlying mechanisms. It is mandatory that additional variables be considered, both independently and in combination with the EF, to improve SCD risk prediction. LV hypertrophy (LVH) is a strong independent risk factor for SCD regardless of the etiology and the severity of symptoms. Concentric and eccentric LV hypertrophy, and even earlier concentric remodeling without hypertrophy, are all associated with increased risk of SCD. In this paper, we summarize the physiology and physiopathology of LVH, review the epidemiological evidence supporting the association between LVH and SCD, briefly discuss the mechanisms linking LVH with SCD, and emphasize the need to evaluate LV geometry as a potential risk stratification tool regardless of the LVEF. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | en |
dc.language.iso | en | en |
dc.source | Heart Failure Reviews | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85109000578&doi=10.1007%2fs10741-021-10134-5&partnerID=40&md5=a8d080d4f24f254e3235c166c5c4367d | |
dc.subject | aortic stenosis | en |
dc.subject | arrhythmogenesis | en |
dc.subject | cardiac patient | en |
dc.subject | cardiomyopathy | en |
dc.subject | cause of death | en |
dc.subject | coronary artery disease | en |
dc.subject | differential diagnosis | en |
dc.subject | disease association | en |
dc.subject | disease classification | en |
dc.subject | disease course | en |
dc.subject | disease severity | en |
dc.subject | echocardiography | en |
dc.subject | epidemiological data | en |
dc.subject | feasibility study | en |
dc.subject | heart arrest | en |
dc.subject | heart arrhythmia | en |
dc.subject | heart electrophysiology | en |
dc.subject | heart failure with preserved ejection fraction | en |
dc.subject | heart left ventricle ejection fraction | en |
dc.subject | heart left ventricle hypertrophy | en |
dc.subject | heart muscle biopsy | en |
dc.subject | heart ventricle arrhythmia | en |
dc.subject | heart ventricle fibrillation | en |
dc.subject | heart ventricle remodeling | en |
dc.subject | high risk patient | en |
dc.subject | human | en |
dc.subject | hypertension | en |
dc.subject | hypertrophic cardiomyopathy | en |
dc.subject | molecular genetics | en |
dc.subject | molecular pathology | en |
dc.subject | nonhuman | en |
dc.subject | pathophysiology | en |
dc.subject | population research | en |
dc.subject | practice guideline | en |
dc.subject | prediction | en |
dc.subject | primary prevention | en |
dc.subject | public health problem | en |
dc.subject | Review | en |
dc.subject | risk factor | en |
dc.subject | risk management | en |
dc.subject | sudden cardiac death | en |
dc.subject | symptom | en |
dc.subject | tachycardia | en |
dc.subject | adverse device effect | en |
dc.subject | complication | en |
dc.subject | heart left ventricle function | en |
dc.subject | heart left ventricle hypertrophy | en |
dc.subject | heart stroke volume | en |
dc.subject | implantable cardioverter defibrillator | en |
dc.subject | physiology | en |
dc.subject | sudden cardiac death | en |
dc.subject | Death, Sudden, Cardiac | en |
dc.subject | Defibrillators, Implantable | en |
dc.subject | Humans | en |
dc.subject | Hypertrophy, Left Ventricular | en |
dc.subject | Risk Factors | en |
dc.subject | Stroke Volume | en |
dc.subject | Ventricular Function, Left | en |
dc.subject | Springer | en |
dc.title | Left ventricular hypertrophy and sudden cardiac death | en |
dc.type | other | en |